Conference Call Participants
Joon Lee – Truist Securities, Inc., Research Division
Julian Pino – Stifel, Nicolaus & Company, Incorporated, Research Division
Luke Herrmann – Robert W. Baird & Co. Incorporated, Research Division
David Amsellem – Piper Sandler & Co., Research Division
Umer Raffat – Evercore ISI Institutional Equities, Research Division
Jason Gerberry – BofA Securities, Research Division
Joseph Thome – TD Cowen, Research Division
So Youn Shim – UBS Investment Bank, Research Division
Uy Ear – Mizuho Securities USA LLC, Research Division
Ami Fadia – Needham & Company, LLC, Research Division
Craig McLean – Wells Fargo Securities, LLC, Research Division
Douglas Tsao – H.C. Wainwright & Co, LLC, Research Division
David Hoang – Deutsche Bank AG, Research Division
Manoj Eradath – Jefferies LLC, Research Division
Presentation
Operator
Greetings, and welcome to the Alkermes plc Conference Call. My name is Rob, and I’ll be your operator for today’s call. [Operator Instructions] Please note that this conference is being recorded.
I’ll now turn the call over to Sandra Coombs, Senior Vice President, Investor Relations and Corporate Affairs. Sandy, you may now begin.
Sandra Coombs
Senior Vice President of Corporate Affairs & Investor Relations
Good morning. Welcome to the Alkermes plc conference call to discuss the top line results of the Vibrance-2 Phase II study of alixorexton in patients with narcolepsy type 2. With me today are Richard Pops, our CEO; and Dr. Craig Hopkinson, our Chief Medical Officer. A press release, along with the slide presentation that we’ll discuss today are available on the Investors section of alkermes.com.
Our discussions during this conference call will include forward-looking statements. Actual results could
